Clinical Effect of Intravitreous Injection of Conbercept on Edema Regression and Visual Acuity Improvement in Patients with Diabetic Macular Edema
Objective To analyze the clinical effect of intravitreal injection of conbercept on edema regression and visual acuity improvement in patients with diabetic macular edema. Methods A total of 80 patients with diabetic macular edema were selected from a hospital from June 2021 to October 2023,into two groups by random number table method,40 cases in each group. The control group was treated with fundus laser photocoagulation alone,while the research group was treated with fundus laser photocoagulation combined with intravitreal injection of conbercept. The regression of edema and visual improvement of the two groups were compared. Results Compared with the control group,the total effective rate of the research group was significantly higher (P<0.05). Compared with the control group after treatment,the central macular thickness,fluorescence area of macular area and fundus bleeding area in the research group were significantly smaller (P<0.05). The levels of anti-vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF),tumor necrosis factor α and interleukin-6 were significantly lower (P<0.05),while the best corrected visual acuity was significantly higher (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion In patients with diabetic macular edema,intravitreal injection of conbercept can significantly improve their vision,promote the regression of edema,and reduce the levels of VEGF,PDGF and pro-inflammatory cytokines,which is worthy of promotion.
万方数据
维普
